Proyecto de evaluación para la creación de un insecticida ecológico a base de la planta neem para el cultivo de arroz en el cantón Daule.

This project is an assessment for the creation of an insecticide-based Eco Neem plant for growing rice in Daule canton of Guayas province, this insecticide called Arro-Ally is made from the plant Neem (Azadirachta indica), a product that will help: maintain ecological balance (soil, air, water), reduce dependence on chemicals, avoid collateral damage in occupational health and direct costs in growing this grass remain, encouraging the farmer who considers that his business is profitable, preventing migration. The study includes a financial feasibility analysis to determine the costs involved in the creation and marketing of insecticide-Allied Arro, I foresee achieving revenue and thus considering criteria based on financial and market research, project feasibility

A Generalized Model for Indoor Location Estimation Using Environmental Sound from Human Activity Recognition

The indoor location of individuals is a key contextual variable for commercial and assisted location-based services and applications. Commercial centers and medical buildings (e.g., hospitals) require location information of their users/patients to offer the services that are needed at the correct moment. Several approaches have been proposed to tackle this problem. In this paper, we present the development of an indoor location system which relies on the human activity recognition approach, using sound as an information source to infer the indoor location based on the contextual information of the activity that is realized at the moment. In this work, we analyze the sound information to estimate the location using the contextual information of the activity. A feature extraction approach to the sound signal is performed to feed a random forest algorithm in order to generate a model to estimate the location of the user. We evaluate the quality of the resulting model in terms of sensitivity and specificity for each location, and we also perform out-of-bag error estimation. Our experiments were carried out in five representative residential homes. Each home had four individual indoor rooms. Eleven activities (brewing coffee, cooking, eggs, taking a shower, etc.) were performed to provide the contextual information. Experimental results show that developing an indoor location system (ILS) that uses contextual information from human activities (identified with data provided from the environmental sound) can achieve an estimation that is 95% correct

A Generalized Model for Indoor Location Estimation Using Environmental Sound from Human Activity Recognition

The indoor location of individuals is a key contextual variable for commercial and assisted location-based services and applications. Commercial centers and medical buildings (e.g., hospitals) require location information of their users/patients to offer the services that are needed at the correct moment. Several approaches have been proposed to tackle this problem. In this paper, we present the development of an indoor location system which relies on the human activity recognition approach, using sound as an information source to infer the indoor location based on the contextual information of the activity that is realized at the moment. In this work, we analyze the sound information to estimate the location using the contextual information of the activity. A feature extraction approach to the sound signal is performed to feed a random forest algorithm in order to generate a model to estimate the location of the user. We evaluate the quality of the resulting model in terms of sensitivity and specificity for each location, and we also perform out-of-bag error estimation. Our experiments were carried out in five representative residential homes. Each home had four individual indoor rooms. Eleven activities (brewing coffee, cooking, eggs, taking a shower, etc.) were performed to provide the contextual information. Experimental results show that developing an indoor location system (ILS) that uses contextual information from human activities (identified with data provided from the environmental sound) can achieve an estimation that is 95% correct

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)